Literature DB >> 25795272

Umbilical cord blood-derived cellular products for cancer immunotherapy.

Jeannette Cany1, Harry Dolstra1, Nina Shah2.   

Abstract

Although the vast majority of experience with umbilical cord blood (CB) centers on hematopoietic reconstitution, a recent surge in the knowledge of CB cell subpopulations as well as advances in ex vivo culture technology have expanded the potential of this rich resource. Because CB has the capacity to generate the entire hematopoietic system, we now have a new source for natural killer, dendritic and T cells for therapeutic use against malignancies. This Review will focus on cellular immunotherapies derived from CB. Expansion techniques, ongoing clinical trials and future directions for this new dimension of CB application are also discussed.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  cancer immunotherapy; cellular therapy; cord blood; expansion

Mesh：

Substances：

Year:  2015        PMID： 25795272     DOI： 10.1016/j.jcyt.2015.03.005

Source DB:  PubMed          Journal:  Cytotherapy        ISSN： 1465-3249            Impact factor:   5.414


  11 in total

1.  Zoledronate increases enrichment, activation and expansion of natural killer cells from umbilical cord blood.

Authors:  Zhijie Ma; Yunhong Wang; Huiyan Kang; Xiaoyun Wu
Journal:  Hum Cell       Date:  2018-06-13       Impact factor: 4.174

2.  Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rgnull mice.

Authors:  Jeannette Cany; Mieke W H Roeven; Janneke S Hoogstad-van Evert; Willemijn Hobo; Frans Maas; Rosalia Franco Fernandez; Nicole M A Blijlevens; Walter J van der Velden; Gerwin Huls; Joop H Jansen; Nicolaas P M Schaap; Harry Dolstra
Journal:  Blood       Date:  2017-11-14       Impact factor: 22.113

3.  Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.

Authors:  Blandine Caël; Jeanne Galaine; Isabelle Bardey; Chrystel Marton; Maxime Fredon; Sabeha Biichle; Margaux Poussard; Yann Godet; Fanny Angelot-Delettre; Christophe Barisien; Christophe Bésiers; Olivier Adotevi; Fabienne Pouthier; Francine Garnache-Ottou; Elodie Bôle-Richard
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 4.  Natural Killer Cells for Therapy of Leukemia.

Authors:  Garnet Suck; Yeh Ching Linn; Torsten Tonn
Journal:  Transfus Med Hemother       Date:  2016-03-22       Impact factor: 3.747

5.  The newborn human NK cell repertoire is phenotypically formed but functionally reduced.

Authors:  Dara M Strauss-Albee; Emily C Liang; Thanmayi Ranganath; Natali Aziz; Catherine A Blish
Journal:  Cytometry B Clin Cytom       Date:  2016-11-08       Impact factor: 3.058

Review 6.  Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.

Authors:  Markus Granzin; Juliane Wagner; Ulrike Köhl; Adelheid Cerwenka; Volker Huppert; Evelyn Ullrich
Journal:  Front Immunol       Date:  2017-04-26       Impact factor: 7.561

7.  Combination of SB431542, Chir9901, and Bpv as a novel supplement in the culture of umbilical cord blood hematopoietic stem cells.

Authors:  Morteza Zarrabi; Elaheh Afzal; Mohammad Hassan Asghari; Marzieh Ebrahimi
Journal:  Stem Cell Res Ther       Date:  2020-11-09       Impact factor: 6.832

8.  Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.

Authors:  Jeetendra Kumar; Vaijayanti Kale; Lalita Limaye
Journal:  Stem Cell Res Ther       Date:  2015-09-25       Impact factor: 6.832

Review 9.  Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.

Authors:  J-F Stoltz; N de Isla; Y P Li; D Bensoussan; L Zhang; C Huselstein; Y Chen; V Decot; J Magdalou; N Li; L Reppel; Y He
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

10.  Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Authors:  U Koehl; C Kalberer; J Spanholtz; D A Lee; J S Miller; S Cooley; M Lowdell; L Uharek; H Klingemann; A Curti; W Leung; E Alici
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.